393 related articles for article (PubMed ID: 25385189)
21. Novel combinations using pemetrexed in malignant mesothelioma.
Gadgeel SM; Pass HI
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S61-6. PubMed ID: 15117427
[TBL] [Abstract][Full Text] [Related]
22. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ; Rusthoven JJ; Symanowski J; Denham C; Kaukel E; Ruffie P; Gatzemeier U; Boyer M; Emri S; Manegold C; Niyikiza C; Paoletti P
J Clin Oncol; 2003 Jul; 21(14):2636-44. PubMed ID: 12860938
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
24. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
25. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
26. Deciduoid pleural mesothelioma in an adolescent.
Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
[No Abstract] [Full Text] [Related]
27. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
28. Pemetrexed-cisplatin combination in mesothelioma.
Reck M; Gatzemeier U
Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
[TBL] [Abstract][Full Text] [Related]
29. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
O'Kane SL; Eagle GL; Greenman J; Lind MJ; Cawkwell L
Lung Cancer; 2010 Feb; 67(2):160-5. PubMed ID: 19450893
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
Rusch VW
J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
[No Abstract] [Full Text] [Related]
31. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
Kao SC; McCaughan B; Muljono A; Boyer M
J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
[No Abstract] [Full Text] [Related]
32. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
33. Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.
Adusumilli PS
Cancer; 2014 Nov; 120(21):3268-71. PubMed ID: 24989696
[No Abstract] [Full Text] [Related]
34. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
35. Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ
Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
[TBL] [Abstract][Full Text] [Related]
36. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
Cihan YB; Ozturk A; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Habib EE; Fahmy ES
Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
[TBL] [Abstract][Full Text] [Related]
39. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
Pinton G; Manente AG; Daga A; Cilli M; Rinaldi M; Nilsson S; Moro L
Mol Cancer; 2014 Oct; 13():227. PubMed ID: 25277603
[TBL] [Abstract][Full Text] [Related]
40. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J; Dundar Y; Dodd S; Dickson R; Walley T
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]